Across TCGA pan-cancer cohorts, C1QTNF9B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated C1QTNF9B data layer compared with 20 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher C1QTNF9B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C1QTNF9B expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

LGG and STAD are the cancer types where C1QTNF9B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	DFS	Median	All	0.077	0.845	<.001	6	view →
STAD	OS	Median	IV	1.000	0.299	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: C1QTNF9B tumor-vs-normal RNA expression · all C1QTNF9B data types